AVXL at a glance
ANAVEX LIFE SCIENCES CORP. (AVXL, SEC CIK 1314052) filed its latest 10-K annual report on November 25, 2025, a 10-Q quarterly report on August 28, 2026, an 8-K current report on September 28, 2026 and Form 4 insider filings as recently as September 28, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of June 30, 2026, 28 institutional investment managers tracked by SignalX reported holding ANAVEX LIFE SCIENCES CORP. (AVXL) shares worth $59.5 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 28 funds
- $59.5M · +0 vs prior quarter
- Latest 8-K
- Sep 28, 2026
- Item 5.07
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $0, unchanged year over year; no products approved for commercial sale
- Profitability not stated; clinical-stage company with no commercial revenue
- Lead compound ANAVEX 2-73 prioritized for early Alzheimer’s disease, Rett syndrome, and Fragile X syndrome
- Other assets ANAVEX 3-71, 1-41, and 1066 de-prioritized; development paused
- Near-term focus on FDA engagement and data-driven regulatory strategy; additional funding or partnerships needed for paused assets
Risk Factors
- Former CEO termination for Cause triggered potential litigation, inquiries, investigations, and enforcement actions
- Arbitration demand filed June 2026 alleging wrongful termination
- New York Supreme Court action filed July 2026 against four independent directors
- FDA, SEC, and Nasdaq proceedings risk management distraction and reputational harm
- Investor, patient, and partner confidence loss could pressure operations and stock price
AI summary of the AVXL 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.07: Submission of Matters to a Vote of Security Holders
- Shareholder vote: 54,239,204 shares represented, equal to approximately 58.51% of outstanding shares
- All six company nominees elected, defeating PVG Asset Management’s six-person activist slate
Item 8.01: Other Events
- FDA granted Anavex’s meeting request on pediatric inclusion in the Phase 3 Rett syndrome trial
- Phase 3 trial ANAVEX 2-73-RS-005 currently advancing in adult Rett syndrome patients
Item EX-99.1: Item EX-99.1
- Nasdaq compliance restored after filing outstanding Q2 and Q3 fiscal 2026 Form 10-Q reports on August 28, 2026
- AVXL common stock continues trading on Nasdaq Global Select Market
Item 8.01: Other Events
- Nasdaq compliance restored after filing delayed 10-Q reports for quarters ended March 31 and June 30, 2026
- Delisting-related risk under Nasdaq Rule 5250(c)(1) removed following August 28, 2026 filings
AI summaries of AVXL 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for AVXL
Don't miss the next AVXL filing
- Alerts as it files. A push when AVXL files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut AVXL, by share count.
- Ask anything. An AI agent that reads every AVXL filing and answers with sources.
AVXL alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Boenisch Sandra | A | Sep 24, 2026 | 20,000 | - |
| Boenisch Sandra | A | Sep 24, 2026 | 25,000 | - |
| Boenisch Sandra | A | Sep 24, 2026 | 25,000 | - |
| Boenisch Sandra | A | Sep 24, 2026 | 25,000 | - |
| MISSLING CHRISTOPHER U | A | Jan 6, 2026 | 125,000 | - |
| Boenisch Sandra | A | Jan 6, 2026 | 12,500 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Operating Income | -$55.8M | -$52.9M | -$51.4M | |
| Net Income | -$47.5M | -$43.0M | -$46.4M | |
| Balance Sheet | ||||
| Total Assets | $154.4M | $135.6M | $103.8M | |
| Equity | $141.9M | $120.3M | $94.9M | |
| ROE | -33.5% | -35.8% | -48.9% | |
| Per Share | ||||
| EPS | $-0.60 | $-0.52 | $-0.54 | |
| Cash Flow | ||||
| Operating CF | -$27.8M | -$30.8M | -$39.0M | |
Source: XBRL data in ANAVEX LIFE SCIENCES CORP. (AVXL)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate AVXL share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 28 | $59.5M |
| Q1 2026 | 28 | $77.5M |
| Q4 2025 | 24 | $82.6M |
| Q3 2025 | 24 | $188.0M |
| Q2 2025 | 24 | $191.2M |
| Q1 2025 | 22 | $113.8M |
| Q4 2024 | 20 | $118.3M |
| Q3 2024 | 16 | $35.7M |
- BlackRock+446.0K (+6%)
- AQR Capital Management+206.2K (+27%)
- Vanguard Capital Management LLC+190.6K (+5%)
- Vanguard Portfolio Management LLC+165.5K (+21%)
- Goldman Sachs Group+86.2K (+11%)
- State Street Corp−2.59M (-57%)
- Citadel Advisors LLC−230.3K (-41%)
- Bank of America Corp−208.9K (-24%)
- Two Sigma Investments−201.3K (-6%)
- Morgan Stanley−162.8K (-46%)
- Millennium Management+60.5K
- StoneX Group Inc.+18.7K
- Renaissance Technologies LLC−276.8K
- Franklin Resources−71.9K
Source: 13F-HR filings on SEC EDGAR (aggregated from 186 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
AVXL filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Sep 28, 2026 | - | Analysis | - |
| 4 | Sep 28, 2026 | - | - | - |
| 8-K | Sep 9, 2026 | - | Analysis | - |
| 8-K | Sep 2, 2026 | - | Analysis | - |
| 10-Q | Aug 28, 2026 | Jun 30, 2026 | Analysis | |
| 10-Q | Aug 28, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Aug 25, 2026 | - | Analysis | - |
| 8-K | Aug 17, 2026 | - | Analysis | - |
| 8-K | Aug 11, 2026 | - | Analysis | - |
| 8-K | Aug 3, 2026 | - | Analysis | - |
| SC 13G | Jul 31, 2026 | - | - | |
| 8-K | Jul 30, 2026 | - | Analysis | - |
| 8-K | Jul 20, 2026 | - | Analysis | - |
| 8-K | Jun 26, 2026 | - | Analysis | - |
| 8-K | May 22, 2026 | - | Analysis | |
| 8-K | May 15, 2026 | - | Analysis | |
| 8-K | May 6, 2026 | - | - | |
| 8-K | Mar 25, 2026 | - | - | - |
| 8-K | Feb 25, 2026 | - | - | - |
| 10-Q | Feb 9, 2026 | Dec 31, 2025 | Analysis | |
| 8-K | Feb 9, 2026 | - | - | |
| 4 | Jan 9, 2026 | - | - | |
| 4 | Jan 9, 2026 | - | - | |
| 10-K | Nov 25, 2025 | Sep 30, 2025 | - | |
| 8-K | Nov 25, 2025 | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ACLX · Arcellx, Inc.Biological Products, (No Diagnostic Substances)
AVXL SEC filings: frequently asked questions
Which institutions hold AVXL stock?
As of June 30, 2026, the largest ANAVEX LIFE SCIENCES CORP. (AVXL) holders among the 13F filers tracked by SignalX were BlackRock ($20.9 million), Vanguard Capital Management LLC ($10.5 million), Two Sigma Investments ($7.9 million), State Street Corp ($5.0 million), AQR Capital Management ($2.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What did AVXL report in its latest 8-K?
ANAVEX LIFE SCIENCES CORP. (AVXL) filed an 8-K on September 28, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). Shareholder vote: 54,239,204 shares represented, equal to approximately 58.51% of outstanding shares.
What are the latest AVXL SEC filings?
ANAVEX LIFE SCIENCES CORP. (AVXL) filed its latest 10-K annual report on November 25, 2025, a 10-Q quarterly report on August 28, 2026, an 8-K current report on September 28, 2026 and a Form 4 insider filing on September 28, 2026.
What is AVXL's SEC CIK number?
ANAVEX LIFE SCIENCES CORP. (AVXL)'s SEC Central Index Key (CIK) is 1314052. EDGAR lists every AVXL filing under that number.
Ask anything about AVXL
The research agent reads AVXL's filings, financials, insider trades and 13F holders, then answers with sources.